Idera Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 88   

Articles published

IDRA 4.67 +0.16 (3.55%)
price chart
Idera Pharmaceuticals: A Star In The Making (IDRA)
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) is a biotechnology company engaged in discovering and developing Toll-Like Receptors (TLRs) antagonists, novel-synthetic DNA and RNA based drug candidates.
Related articles »  
Stock Watch: Idera Pharmaceuticals Inc (NASDAQ:IDRA)
[Globe NewsWIRE] Idera Pharmaceuticals Inc (NASDAQ:IDRA) (TREND ANALYSIS), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Vincent ...
Idera Pharmaceuticals Inc Short Interest Falls  Rock Hill Daily
Friday Stocks To Watch: Campbell Soup Co , Idera Pharmaceuticals Inc , AGCO ...  Winston View
Idera Pharmaceuticals (IDRA) Marked As A Dead Cat Bounce Stock
Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, is engaged in the discovery and development of novel therapeutics that modulate immune responses through toll-like receptors (TLRs) in the United States.
Stock to Watch: Idera Pharmaceuticals Inc (NASDAQ:IDRA)  Markets Wired
Insider Buying: Vincent Milano Purchases 200000 Shares of Idera ...  The Legacy
Related articles »  
Idera Pharmaceuticals Inc.: Idera Announces Leadership Appointments
26, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing immune-modulating and gene silencing therapies for cancer and rare diseases, today announced the appointments of R.
Idera Announces Leadership Appointments  MarketWatch
Idera Pharmaceuticals Going Into 2015 (IDRA)
Idera Pharmaceuticals Inc. (NASDAQ:IDRA) is set to enter 2015 with a number of important developments happening during the year.
Related articles »  
Short Interest of Idera Pharmaceuticals Inc Drops by 4.1%
Idera Pharmaceuticals Inc (NASDAQ:IDRA), A sharp reduction of 347,282 shares or 4.1% was observed in the short interest of Idera Pharmaceuticals, Inc. The interest on December 31,2014 came in at 8,046,096 shares and as per the average daily trading of ...
Stocks Underperform for the Week: UTi Worldwide Inc , Idera Pharmaceuticals Inc
UTi Worldwide Inc. (NASDAQ:UTIW) has lost 0.79% during the past week and dropped 4.71% in the past 4 weeks. The shares are however, marginally negative as compared to the S&P 500 for the past week with a loss of 2.36%.
First Call Rating Update on Idera Pharmaceuticals Inc  Wall Street Pulse
Stock Insights on Idera Pharmaceuticals Inc (NASDAQ:IDRA)
[Globe Newswire] Idera Pharmaceuticals Inc (NASDAQ:IDRA) a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, today announced that the U.S.
Traders Alert - Idera Pharmaceuticals (IDRA), Sunstone Hotel Investors Inc ...  Techsonian (press release)
5 Active Stocks: Idera Pharmaceuticals (NASDAQ:IDRA), QUALCOMM ...  Property Mentor
Related articles »  
Idera Pharmaceuticals (IDRA) Stock Rises After Cancer Drug Shows Anti-Tumor ...
Idera Pharmaceuticals Inc (NASDAQ:IDRA) announced after markets closed Tuesday that its immunotherapy intratumoral injection candidate, IMO-2055, showed anti-tumor activity in combination with Bristol-Myers Squibb Co's (NYSE:BMY) Yervoy against a ...
Idera Pharmaceuticals Announces Cancer Immunotherapy Regimen With ...  GlobeNewswire (press release)
Idera Pharma (IDRA) Issues Encouraging Update on IMO-2055 Combo in ...  StreetInsider.com (subscription)
Related articles »  
Idera Pharmaceuticals Names Vincent J. Milano Chief Executive Officer
CAMBRIDGE, Mass., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for cancers and rare diseases, announced that it has appointed Vincent ...
Idera Pharma Appoints Vincent Milano As CEO  Nasdaq
CEO who oversaw ViroPharma sale named to same role at Idera  Boston Business Journal (blog)
Related articles »